Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Mark G Wise, James A Karlowsky, Naglaa Mohamed, Elizabeth D Hermsen, Shweta Kamat, Andy Townsend, Adrian Brink, Alex Soriano, David L Paterson, Luke S P Moore, Daniel F Sahm
OBJECTIVES: To report trends in carbapenem resistance and difficult-to-treat resistance (DTR) among clinical isolates of Gram-negative priority pathogens collected by the ATLAS global surveillance program from 2018 to 2022. METHODS: Reference broth microdilution testing was performed in a central laboratory for 79,214 Enterobacterales, 30,504 Pseudomonas aeruginosa, and 13,500 Acinetobacter baumannii-calcoaceticus complex isolates collected by a constant set of 157 medical centres in 49 countries in Asia Pacific (APAC), Europe (EUR), Latin America (LATAM), Middle East-Africa (MEA), and North America (NA) regions...
April 10, 2024: Journal of Global Antimicrobial Resistance
#2
JOURNAL ARTICLE
Ricardo Rabagliati, Grace Salazar, Giancarlo Pérez-Lazo, Maria Paz Iturrieta, Diana Portillo, Carmen Soria-Segarra, María José Ojeda, Jimena Flores, Margarita Galarza, Roxana Sandoval-Ahumada, Pablo Cartes Aguilera, Lady Dimitrakis, Fabiola Avelga Reinoso, Patricia Garcia
BACKGROUND: Febrile neutropenia is a life-threatening condition commonly observed in patients with hematologic malignancies. The aim of this article is to provide updated knowledge about bloodstream infections in febrile neutropenia episodes within the Andean region of Latin America. METHOD: This retrospective study was based in 6 hospitals in Chile, Ecuador, and Peru and included adult patients with acute leukemia or lymphoma and febrile neutropenia between January 2019 and December 2020...
March 2024: Open Forum Infectious Diseases
#3
JOURNAL ARTICLE
Qiwen Yang, Shweta Kamat, Naglaa Mohamed, Rafael Ricardo Valdez, Stephen Lin, Ming Su, Alvaro Quintana, Pattarachai Kiratisin, Ana Patricia Rodríguez-Zulueta, Adrian Brink
BACKGROUND: Antimicrobial resistance (AMR) data in the pediatric population are limited, particularly in developing countries. This study assessed the AMR profile and key resistance phenotypes and genotypes for Gram-negative bacteria (GNB) isolates collected as part of the Antimicrobial Testing Leadership and Surveillance program from pediatric patients in Latin America, Africa-Middle East, and Asia in 2016-2020 versus 2011-2015. METHODS: Minimum inhibitory concentrations by broth microdilution methodology were interpreted per the Clinical and Laboratory Standards Institute...
August 10, 2023: Journal of the Pediatric Infectious Diseases Society
#4
JOURNAL ARTICLE
Pattarachai Kiratisin, Marie Kempf, Gregory Stone, Eric Utt
OBJECTIVES: The objective of this study was to assess the distribution and antimicrobial susceptibility of P. aeruginosa isolates against ceftazidime-avibactam (CAZ-AVI) and a panel of comparator agents collected globally and in each region from 2017-2020 from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program. METHODS: Susceptibility and minimum inhibitory concentration (MIC) of all P. aeruginosa isolates were determined using broth microdilution methodology for according to the Clinical and Laboratory Standards Institute guidelines...
July 6, 2023: Journal of Global Antimicrobial Resistance
#5
JOURNAL ARTICLE
James A Karlowsky, Sibylle H Lob, Mark A Estabrook, Fakhar Siddiqui, C Andrew DeRyke, Katherine Young, Mary R Motyl, Daniel F Sahm
OBJECTIVES: To determine susceptibility profiles and β-lactamase content for ceftolozane/tazobactam-resistant and imipenem/relebactam-resistant Pseudomonas aeruginosa isolates collected in eight global regions during 2016-21. METHODS: Broth microdilution MICs were interpreted using CLSI breakpoints. PCR to identify β-lactamase genes or WGS was performed on selected isolate subsets. RESULTS: Ceftolozane/tazobactam-resistant [from 0...
June 2023: JAC-antimicrobial resistance
#6
JOURNAL ARTICLE
Walter Martinez Loaiza, Anny Katheryne Rivera Ruiz, Cristian Camilo Ospina Patiño, Mónica Chavez Vivas
PURPOSE: In this review we present the status of the prevalence of bacteria resistant to antibiotics and the main antibiotic resistance genes that are reported in infections acquired in intensive care units (ICU) around the world. METHODS: A systematic review based on the PRISMA guide was carried out, from the Science Direct, Redalyc, Scopus, Hinari, Scielo, Dialnet, PLOS, ProQuest, Taylor, Lilacs and PubMed/Medline databases. Inclusion criteria of this review were original research study published in a scientific journal in a 10-year time span from 1 January 2017 and 30 April 2022...
2023: Acta Medica (Hradec Králové)
#7
JOURNAL ARTICLE
James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, Jacqueline Pavia, C Andrew DeRyke, Katherine Young, Mary R Motyl, Daniel F Sahm
Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa are being isolated from patient specimens with increasing frequency in Latin America and worldwide. The current study provides an initial description of the in vitro activity of Imipenem/Relebactam (IMR) against non-Morganellaceae Enterobacterales (NME) and P. aeruginosa infecting hospitalized patients in Latin America. From 2018 to 2020, 37 clinical laboratories in nine Latin American countries participated in the SMART global surveillance program and contributed 15,466 NME and 3408 P aeruginosa isolates...
May 8, 2023: Brazilian Journal of Infectious Diseases
#8
JOURNAL ARTICLE
Ana C Gales, Gregory Stone, Daniel F Sahm, Mark G Wise, Eric Utt
OBJECTIVES: To assess the global and regional distribution of ESBLs in Enterobacterales and carbapenemases in Enterobacterales and Pseudomonas aeruginosa. METHODS: Antimicrobial susceptibility of isolates collected from ATLAS (2017-2019) was determined per CLSI guidelines. Enterobacterales exhibiting meropenem MICs ≥2 mg/L and/or ceftazidime/avibactam and/or aztreonam/avibactam MICs ≥16 mg/L, Escherichia coli and Klebsiella pneumoniae with aztreonam and/or ceftazidime MICs ≥2 mg/L, and P...
July 5, 2023: Journal of Antimicrobial Chemotherapy
#9
JOURNAL ARTICLE
Mark G Wise, James A Karlowsky, Elkin Lemos Luengas, Rafael R Valdez, Daniel F Sahm
INTRODUCTION: The incidence of antimicrobial resistance is increasing in many parts of the world. The focus of this report is to examine changes in antimicrobial resistance epidemiology among clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in six Latin American countries as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program from 2015 to 2020, with a focus on the in vitro activity of ceftazidime-avibactam against Multidrug-Resistant (MDR) isolates...
March 25, 2023: Brazilian Journal of Infectious Diseases
#10
JOURNAL ARTICLE
María Fernanda Mojica, Elsa De La Cadena, Juan Carlos García-Betancur, Jessica Porras, Isabella Novoa-Caicedo, Laura Páez-Zamora, Christian Pallares, Tobias Manuel Appel, Marcela A Radice, Paulo Castañeda-Méndez, Ana C Gales, José M Munita, María Virginia Villegas
Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales ( n = 2,235) and P. aeruginosa ( n = 492) that were collected between 2016 and 2017 from five Latin American countries, we investigated the molecular resistance mechanisms to CZA of 127 (18/2,235 [0.8%] Enterobacterales and 109/492 [22.1%] P...
March 6, 2023: MSphere
#11
JOURNAL ARTICLE
María F Mojica, Elsa De La Cadena, Rafael Ríos, Juan Carlos García-Betancur, Lorena Díaz, Jinnethe Reyes, Cristhian Hernández-Gómez, Marcela Radice, Ana C Gales, Paulo Castañeda Méndez, José M Munita, Christian José Pallares, José R W Martínez, María Virginia Villegas
OBJECTIVES: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. METHODS: Clinical isolates of P. aeruginosa ( n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico...
2022: Frontiers in Microbiology
#12
JOURNAL ARTICLE
Juan Carlos García-Betancur, Elsa De La Cadena, María F Mojica, Cristhian Hernández-Gómez, Adriana Correa, Marcela A Radice, Paulo Castañeda-Méndez, Diego A Jaime-Villalon, Ana C Gales, José M Munita, María Virginia Villegas
BACKGROUND: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known β-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents...
August 13, 2022: Antibiotics
#13
JOURNAL ARTICLE
Heather Tate, Sherry Ayers, Epiphanie Nyirabahizi, Cong Li, Stacey Borenstein, Shenia Young, Crystal Rice-Trujillo, Sanchez Saint Fleurant, Sonya Bodeis-Jones, Xunde Li, Melissa Tobin-D'Angelo, Victoriya Volkova, Rachel Hardy, Lisa Mingle, Nkuchia M M'ikanatha, Laura Ruesch, Chris A Whitehouse, Gregory H Tyson, Errol Strain, Patrick F McDermott
In 2019, the United States National Antimicrobial Resistance Monitoring System (NARMS) surveyed raw salmon, shrimp, and tilapia from retail grocery outlets in eight states to assess the prevalence of bacterial contamination and antimicrobial resistance (AMR) in the isolates. Prevalence of the targeted bacterial genera ranged among the commodities: Salmonella (0%-0.4%), Aeromonas (19%-26%), Vibrio (7%-43%), Pseudomonas aeruginosa (0.8%-2.3%), Staphylococcus (23%-30%), and Enterococcus (39%-66%). Shrimp had the highest odds (OR: 2...
2022: Frontiers in Microbiology
#14
JOURNAL ARTICLE
Daniela Cejas, Alan Elena, Francisco E González-Espinosa, Lucia Pallecchi, Carlos Vay, Gian Maria Rossolini, Gabriel Gutkind, Vincenzo Di Pilato, Marcela Radice
OBJECTIVE: to describe two blaKPC-2 plasmids recovered from P. aeruginosa isolates belonging to the ST654 and ST235 high-risk clones, and to compare with complete sequences of blaKPC-2 harboring plasmids available in public databases. METHODS: Antimicrobial susceptibility was determined according to CLSI guidelines. Genomes were sequenced using an Illumina MiSeq platform and blaKPC-2 plasmid sequences were achieved using MinION platform. Sequences were analyzed using Unicycler and RAST...
April 25, 2022: Journal of Global Antimicrobial Resistance
#15
JOURNAL ARTICLE
James A Karlowsky, Krystyna M Kazmierczak, Maria Lavínea Novis de Figueiredo Valente, Elkin Lemos Luengas, Monique Baudrit, Alvaro Quintana, Paurus Irani, Gregory G Stone, Daniel F Sahm
The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to 2019. In vitro activities of ceftazidime-avibactam and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Overall, 98.1% of Enterobacterales and 86.9% of P. aeruginosa isolates were susceptible to ceftazidime-avibactam...
2021: Brazilian Journal of Infectious Diseases
#16
JOURNAL ARTICLE
Helio S Sader, Mariana Castanheira, Leonard R Duncan, Rodrigo E Mendes
BACKGROUND: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). OBJECTIVES: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from patients hospitalized with skin and soft tissue infections (SSTIs) in several countries around the world...
December 2021: International Journal of Infectious Diseases: IJID
#17
JOURNAL ARTICLE
Pattarachai Kiratisin, Krystyna Kazmierczak, Gregory G Stone
OBJECTIVES: This study reports antimicrobial activity for ceftazidime-avibactam and comparators against carbapenemase-producing Enterobacterales (N = 1,992) and carbapenemase-producing Pseudomonas aeruginosa (N = 784) collected in Africa/Middle East, Asia/South Pacific, Europe and Latin America (2016-2018). METHODS: MICs and susceptibility were determined using broth microdilution methodology and EUCAST breakpoints. Genes encoding carbapenemases were detected using multiplex PCR assays...
August 31, 2021: Journal of Global Antimicrobial Resistance
#18
JOURNAL ARTICLE
D Piérard, G G Stone
BACKGROUND: This antimicrobial surveillance study reports in vitro antimicrobial activity and susceptibility data for a panel of agents against respiratory isolates of Enterobacterales and Pseudomonas aeruginosa. METHODS: Isolates from respiratory specimens were collected in Africa/Middle East, Asia/South Pacific, Europe and Latin America between 2016 and 2018, as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program. Broth microdilution methodology was used to quantify minimum inhibitory concentrations, from which rates of susceptibility were determined using EUCAST breakpoints (version 10)...
June 23, 2021: BMC Infectious Diseases
#19
JOURNAL ARTICLE
Victor Daniel Rosenthal, Wieslawa Duszynska, Bat-Erdene Ider, Vaidotas Gurskis, Majeda A Al- Ruzzieh, Sheila Nainan Myatra, Debkishore Gupta, Souad Belkebir, Namita Upadhyay, Farid Zand, Subhash Kumar Todi, Mohit Kharbanda, Pravin K Nair, Shakti Bedanta Mishra, Gustavo Chaparro, Yatin Mehta, Dolatsinh Zala, Jaroslaw Janc, Guadalupe Aguirre Avalos, Daisy Aguilar De Morós, Blanca Estela Hernandez Chena, Emrah Gün, Nefise Oztoprak, Dincer Yildizdas, Mona Moheyeldin Abdelhalim, Suna Secil Ozturk Deniz, Chin Seng Gan, Nguyen Viet Hung, Vito L Tanzi, Abeer Aly Omar, Achilleas Gikas, Amani Ali El-Kholy, Amina Barkat, Anjeela Koirala, Antonio Cerero Gudiño, Asma Bouziri, Katherine Gomez Nieto, Dale Fisher, Eduardo A Medeiros, Estuardo Salgado Yepez, Florin Horhat, Hala Mounir Moustafa Agha, Julio César Vimercati, Victoria Villanueva, Kushlani Jayatilleke, Le Thi Thu Nguyet, Lul Raka, María Guadalupe Miranda Novales, Michael Mihailov Petrov, Anucha Apisarnthanarak, Nadia Tayyab, Naheed Elahi, Nepomuceno Mejia, Rayo Morfin Otero, Safa Al-Khawaja, Tanja Anguseva, Umesh Gupta, Vladislav A Belskii, Wan Rahiza Wan Mat, Edwin Giovanny Chapeta Parada, Humberto Guanche Garcell, Nayide Barahona Guzmán, Anju Mathew, Kavita Raja, Saroj Kumar Pattnaik, Nirav Pandya, Aruna Ananda Poojary, Rajesh Chawla, Tahsine Mahfouz, Souha Kanj Shararah, Vesna Mioljevic, Sona Hlinkova, Mariana Mrazova, Hail M Al-Abdely, Ertugrul Guclu, Asu Ozgultekin, Volkan Baytas, Recep Tekin, Ata Nevzat Yalçın, Nurettin Erben
BACKGROUND: We report the results of INICC surveillance study from 2013 to 2018, in 664 intensive care units (ICUs) in 133 cities, of 45 countries, from Latin-America, Europe, Africa, Eastern-Mediterranean, Southeast-Asia, and Western-Pacific. METHODS: Prospective data from patients hospitalized in ICUs were collected through INICC Surveillance Online System. CDC-NHSN definitions for device-associated healthcare-associated infection (DA-HAI) were applied. RESULTS: We collected data from 428,847 patients, for an aggregate of 2,815,402 bed-days, 1,468,216 central line (CL)-days, 1,053,330 mechanical ventilator (MV)-days, 1,740,776 urinary catheter (UC)-days...
April 23, 2021: American Journal of Infection Control
#20
JOURNAL ARTICLE
Daniela Cristina Tartari, Caetana Paes Zamparette, Graciele Martini, Sandra Christakis, Luiz Henrique Costa, Alessandro Conrado de Oliveira Silveira, Thaís Cristine Marques Sincero
BACKGROUND: The KPC carbapenemase is worldwide disseminated mostly by plasmids. However, in Pseudomonas aeruginosa chromosomal mutations have been more frequently responsible for resistance to carbapenems than the acquisition of mobile elements harboring carbapenemases genes. Indeed, although uncommon, KPC-2-producing P. aeruginosa has appeared more frequently, including in Brazil. OBJECTIVES: To report the first genomic analysis of a KPC-2 plasmid-mediated in an extensively drug-resistant P...
March 28, 2021: Journal of Global Antimicrobial Resistance
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
